- Home
- DOUG vs CMPX Comparison
DOUG vs CMPX Comparison
Compare DOUG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | CMPX |
|---|---|---|
| Founded | 1911 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 752.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DOUG | CMPX |
|---|---|---|
| Price | $2.47 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.44 |
| AVG Volume (30 Days) | 298.0K | ★ 1.8M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,030,928,000.00 | N/A |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.67 | N/A |
| 52 Week Low | $1.48 | $1.33 |
| 52 Week High | $3.20 | $5.86 |
Technical Indicators
Market Signals| Indicator | DOUG | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 51.72 |
| Support Level | $2.66 | $4.83 |
| Resistance Level | $2.90 | $5.32 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 1.12 | 27.03 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.